Pavanjit Brar
Nurse Practitioner · Torrance, CANPI 1033250774
Payments from drug & device makers
Across 99 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$475
- Pfizer$353
- Astellas Pharma US Inc$238
- Lilly USA, LLC$219
- Novo Nordisk$180
- GSK$124
- plus $455 from 11 others
What the payments were for
- Food & beverage$1,97196%
- Education$734%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $475 |
| Pfizer | 17 | $353 |
| Astellas Pharma US Inc | 9 | $238 |
| Lilly USA, LLC | 10 | $219 |
| Novo Nordisk | 10 | $180 |
| GSK | 5 | $124 |
| Amgen(2 entities) | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $69 |
| Exact Sciences | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Intra-sana Laboratories | 2 | $33 |
| Phadia US Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Merck | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$2,044 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 14 | $22,252 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,468 |
| Levothyroxine Sodium | 76 | $933 |
| Atorvastatin Calcium | 97 | $889 |
| Rosuvastatin Calcium | 34 | $646 |
| Omeprazole | 36 | $447 |
| Metoprolol Succinate | 27 | $422 |
| Amlodipine Besylate | 66 | $347 |
| Enalapril Maleate | 26 | $340 |
| Losartan Potassium | 51 | $325 |
| Lisinopril | 52 | $285 |
| Sertraline Hcl | 21 | $238 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $236 |
| Gabapentin | 28 | $221 |
| Metformin Hcl | 19 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $475 | $22,25214 claims |
| PfizerPaxlovid | $353 | $015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Torrance
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.